The antitrypanosomal drug melarsamine hydrochloride (MelCy) (trade name, Cymelarsan) is a melaminophenylarsine made by conjugation of one equivalent of melarsen oxide and two equivalents of cysteamine. Immediately after it was dissolved in water, the compound was found to exist as an equilibrium mixture containing MelCy (43%), MelCy which had lost one cysteamine moiety (MelCy -1; 24%), melarsen oxide (33%), and free cysteamine. Small amounts (<1%) of the oxidation products derived from the last two components were also formed (cystamine and sodium melarsen). On incubation at room temperature, the MelCy content decreased steadily, with an associated increase in the melarsen oxide and sodium melarsen contents. After 5 days in solution at room temperature, 27% of the arsenical agent was MelCy, 14% was MelCy -1, 42% was melarsen oxide, and 17% was sodium melarsen. Since H202 production was detectable in MelCy or cysteamine solutions and the addition of small amounts of exogenous H202 readily converted the trivalent melarsen oxide to the pentavalent sodium melarsen, it is hypothesized that the nonenzymatic conversion of cysteamine to cystamine produced H202, which then oxidized melarsen oxide to sodium melarsen. Similar time course experiments showed that melarsonyl potassium and melarsoprol were more stable in solution.
African trypanosomiasis, which is caused by Trypanosoma brucei gambiense and T. brucei rhodesiense, remains a major tropical health problem, with an estimated 50 million people at risk of infection (16) . Infection of animals with the related species T. brucei brucei, T. evansi, and T. equiperdum restricts the rearing of livestock over an area of approximately 107 km2 (16) . Treatment of the secondary, cerebral stage of trypanosomiasis has relied primarily on the melaminophenylarsine melarsoprol (MelB; Fig. 1 ), which was introduced in 1947 (6) . MelB is insoluble in water and is administered by intravenous injection as a propylene glycol solution (1) . This arsenical agent is frequently associated with a number of serious side effects, particularly an arsenical agent-induced encephalopathy (7, 12) , and the solvent is a powerful irritant that often causes thrombophlebitis (1) . Water-soluble arsenical agents such as melarsonyl potassium (MelW; Fig. 1 ) have also been synthesized, but showed little improvement over MelB (1) .
Recently, a new, water-soluble trivalent arsenical agent, melarsamine hydrochloride (MelCy; Fig. 1 ) (trade name, Cymelarsan), has been shown to be very effective against T. brucei brucei, T. evansi, and T. equiperdum in camels, buffalo, goats, and pigs and in vitro (10, 11, (17) (18) (19) . The drug was also found to be effective against diminazene aceturate-resistant T. brucei bnrcei and T. evansi (17) , is at least 2 to 2.5 times more effective than MelW (18) , and has also been useful as part of combination therapies in mouse models of secondary trypanosomiasis (8, 9) . On the basis of the results of those experiments, MelCy has been licensed for use against trypanosomiasis in animals. In the study described here, we examined the properties of MelCy in solution and found that the compound is unstable and that several dissociation products are formed.
MATERIALS AND METHODS
Compounds. MelCy, trivalent melarsen oxide, MeiW, MeOB, and pentavalent melarsen (as the sodium salt) were all provided by Specia, Rhone-Poulenc (Paris, France). Cysteamine and cystamine were acquired from the Sigma Chemical Co. (Gillingham, United Kingdom), and high-pressure liquid chromatography (HPLC)-grade 1-propanol was acquired from BDH (Poole, United Kingdom). Camphor sulfonic acid and fluorescamine were obtained from the Aldrich Chemical Co. (Gillingham, United Kingdom). All water was filtered and deionized by the Millipore Milli-Q50 system (Watford, United Kingdom). HPLC analyses. All HPLC analyses were performed with Beckman model 110B pumps (High Wycombe, United Kingdom) equipped with a model 167 variable-wavelength spectrophotometer and an Altex 210A manual injection valve (Beckman Instruments) with a 10-pl loop. All data were collected, stored, and analyzed by using Beckman System Gold operating software. The chromatographic conditions used were substantially those published previously (2 octadecylsilane column (250 by 4.6 mm), with a 5-,um particle size and a flow rate of 1.0 ml/min.
Experimental solutions. Stock solutions (all 10 mM) of MelCy were made in distilled water or 60 mM sodium phosphate-44 mM NaCl buffer (pH 7.4), stock solutions of melarsen oxide were made in dimethylformamide, stock solutions of melarsen were made in 0.1 M HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (pH 7.8), stock solutions of MelB were made in 20% propylene glycol, and stock solutions of MelW, cysteamine, or cystamine were made in distilled water. In mixing experiments, aliquots from all stock solutions used were diluted in 20% propylene glycol to accommodate compounds insoluble in aqueous media. Linear standard addition curves were determined for melarsen oxide (0.05 to 6.0 nmol per injection), cysteamine (0.5 to 8.0 nmol per injection), melarsen (0.1 to 1.25 nmol per injection), and cystamine (0.05 to 4.0 nmol per injection). For stability studies, stock solutions were kept at room temperature and were periodically sampled and diluted to 1 mM in distilled water, and 10 nmol was analyzed by HPLC. The effect of exogenous H202 was analyzed by HPLC following the addition of 1 ,ul of H202 (30% [vol/vol]) per ml to 1 mM melarsen oxide in 20% propylene glycol. Endogenous H202 formation was measured enzymatically (13) pounds were present ( Fig. 2A) . The peaks labelled c and d in Fig. 2 clearly retained both the phenyl ring, as measured by UV spectrophotometry at 280 nm (lower trace), and the cysteamine portion of the compound, as measured by fluorometry (upper trace). In contrast, the compounds indicated by the peaks labelled a and b were positive only for amino groups, and the compounds indicated by the peaks labelled e and f were positive only for phenyl groups. By coelution studies, peaks a and b were identified as cysteamine and cystamine, respectively, and likewise, peaks e and f were found to coelute with melarsen and melarsen oxide, respectively. Peak d was calculated to be 2.09 ± 0.06 (n = 31) times as fluorescent per UV unit as peak c. Therefore, peak d appeared to be intact MelCy, whereas peak c was MelCy which had lost one cysteamine (MelCy -1).
Immediately upon dissolution in distilled water, the initial relative disposition of the arsenical compound was found to be 43% MelCy, 24% MelCy -1, 33% melarsen oxide, and <1% melarsen. Over time, this balance changed, such that the relative content, after 114 h, was 27% MelCy, 14% MelCy -1, 42% melarsen oxide, and 17% melarsen (Fig. 2B) . In a similar manner, there was a noticeable decrease in the cysteamine/ cystamine ratio over time. The time-dependent degradation of MelCy and the formation of cystamine and melarsen can clearly be seen in Fig. 3 .
Solutions of melarsen oxide are known to be stable in the presence of oxygen (15) (data not shown). In contrast, the trivalent melarsen oxide present in aerobic solutions of MelCy was converted in a time-dependent manner to pentavalent melarsen (Fig. 3) . Since solutions of both 1 mg of cysteamine and MelCy per ml produced H202 (23 and 2.5 nmol/ml, respectively, after 45 min at room temperature), it was possible that the H202 produced endogenously could be converting melarsen oxide to melarsen. This possibility was confirmed by the addition of an eightfold excess of H202, which resulted in the conversion of approximately 50% of the melarsen oxide to melarsen within 1 h (Fig. 4) . In addition, incubation of MelCy in water under anaerobic conditions inhibited the formation of cystamine and melarsen (data not shown).
All of these results are consistent with the scheme given in Fig. 5 . Immediately upon dissolution, MelCy forms an equilibrium mixture of MelCy, MelCy -1, melarsen oxide, and cysteamine. On storage under aerobic conditions, cysteamine is oxidized to form cystamine and H202, which, in turn, oxidizes melarsen oxide to melarsen. Removal of cysteamine and melarsen oxide from the mixture perturbs the equilibrium conditions, resulting in further dissociation of MelCy and MelCy -1. It appears the MelCy has a higher stability constant than melarsen oxide-glutathione or melarsen oxide-cysteine conjugates, because the last two compounds cannot be detected by HPLC (5).
Because MelCy was unstable in the presence of oxygen, similar experiments were also performed with MelW and MelB. Like MelCy, MelW was unstable, but it appeared to break down at a much slower rate ( Fig. 6A and B) . The four peaks resulting from the decomposition of MelW were melarsen oxide, sodium melarsen, and two unidentified compounds. Over the same time period, there was no detectable degradation of MelB (Fig. SC and D) (5, 19) . However, melarsen oxide is generally considered to be too toxic for direct administration (6) , and is therefore administered as less toxic dithiol conjugates. These compounds must first be converted to melarsen oxide to have direct activity. MelCy, which is more readily converted than MelW or MelB to melarsen oxide in solution, might be expected to have greater activity. This is indeed the case when comparing MelCy, MelW, and MelB as treatments against acute infections in which the central nervous system is not involved (4, 18) .
However, Jennings (9) has shown that MelCy is only a marginally better treatment against a model of cerebral trypanosomiasis, which may reflect difficulties in permeability across the blood-brain barrier. In addition, T. brucei brucei selected for resistance to sodium melarsen is also resistant to melarsen oxide, MelW, MelB, and MelCy (4) (data not shown), primarily because of alterations in a common transport system (3). Given the above observations, MelCy is unlikely to be of any advantage in the treatment of arsenic-resistant trypanosomiasis, but it may have other solubility or pharmacokinetic properties that are superior to those of MelB.
Pentavalent melarsen is much less active than the trivalent melarsen oxide (4), presumably because of the need for metabolic reduction to melarsen oxide for activity (15) . Because the melarsen content of a solution of MelCy increases on storage, we would recommend that MelCy be injected immediately after dissolution to minimize the accumulation of the less active pentavalent arsenical agent.
The nature of MelCy in solution indicates that the pharmacology of the compound is likely to be rather complicated. The existing pharmacokinetic values (14) determined by monitoring total arsenic by atomic absorption and total trypanocidal activity by bioassay are thus incomplete and need to be reexamined by techniques that are capable of separating multiple arsenical compounds from biological samples.
